

VU Research Portal

Risk-based allocation and optimal duration of adjuvant treatment in stage II colon cancer

Jongeneel, Gabriëlle

2021

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Jongeneel, G. (2021). *Risk-based allocation and optimal duration of adjuvant treatment in stage II colon cancer: Model-based evaluations to provide guidance in the decision making process*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENT

Chapter 1

General introduction	7
----------------------	---

Chapter 2

Estimating adjuvant treatment effects in stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data	19
<i>International Journal of Cancer. 2020 Jun 1;146(11):2968-2978</i>	

Chapter 3

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: a prospective cohort study	49
<i>International Journal of Cancer. 2021 Jun 1;148(11):2702-2711</i>	

Chapter 4

Modeling Personalized Adjuvant Treatment in Early stage colon cancer (PATTERN)	75
<i>The European Journal of Health Economics. 2020 Sep;21(7):1059-1073</i>	

Chapter 5

Model-based evaluation of the cost-effectiveness of 3 versus 6 months adjuvant chemotherapy in high-risk stage II colon cancer patients	109
<i>Therapeutic advances in gastroenterology. 2020 Sep 16;13:1756284820954114</i>	

Chapter 6

Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients.	129
<i>Therapeutic advances in gastroenterology. 2021 Mar 12;14:1756284821995715</i>	

Chapter 7

Early cost-effectiveness analysis of risk-based selection for adjuvant treatment in stage II colon cancer: the potential of consensus molecular subtypes	161
<i>Accepted by Cancer Epidemiology, Biomarkers & Prevention</i>	

Chapter 8

Summary and general discussion	197
--------------------------------	-----

Appendices

Nederlandse samenvatting	211
List of publications	215
Dankwoord	217